(R)-4-Methyloxazolidin-2-one → (R)-4-methyl-3-[5-(4-p-tolyloxypiperidine-1-carbonyl)pyridin-2-yl]oxazolidin-2-one
Reaktionsgleichung
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH3:24][C@@H:25]1[CH2:29][O:28][C:27](=[O:30])[NH:26]1>>[CH3:24][C@@H:25]1[CH2:29][O:28][C:27](=[O:30])[N:26]1[C:2]1[CH:3]=[CH:4][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:6][N:7]=1Komponenten
3
Versuchsvorschrift
By reaction and treatment in the same manner as in Example 40 and using (6-bromopyridin-3-yl)(4-p-tolyloxypiperidin-1-yl)methanone (1.2 g) described in Preparation Example 28 and (R)-4-methyloxazolidin-2-one (364 mg) described in Preparation Example 25, the title compound (200 mg) was obtained.
Aufarbeitung
- customBy reaction and treatment in the same manner as in Example 40
- customdescribed in Preparation Example 25
Quellen und Nachweise
- ORD-Eintrag
- ord-e3e087ddf7ec46f692a18631ff0115b1
- Quelldatensatz
- uspto-grants-2013_01
- Patentnummer
- US08354401B2
Notizen zur Reaktion
Wird geladen…